Review of non-surgical treatment options for Peyronie's Disease

International Journal of Impotence Research

Volumn 24, Issue 1, 2012, Pages 1-10

  Larsen, S M ^a   Levine, L A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

intralesional injection; non surgical; oral therapy; Peyronie's disease; traction

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; CARNITINE; COLCHICINE; COLLAGENASE; CORTICOSTEROID; INTERFERON; NICARDIPINE; PENTOXIFYLLINE; PROCARBAZINE; SUPEROXIDE DISMUTASE; TAMOXIFEN CITRATE; VERAPAMIL;

ALOPECIA; ANGINA PECTORIS; ANOREXIA; APLASTIC ANEMIA; ATROPHY; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CONSERVATIVE TREATMENT; DIARRHEA; DIZZINESS; DYSESTHESIA; DYSPEPSIA; ECCHYMOSIS; ELECTROCONVULSIVE THERAPY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IMMUNE DEFICIENCY; INDIGESTION; LEUKOPENIA; LIVER TOXICITY; MYALGIA; NAUSEA; PANCYTOPENIA; PATHOGENESIS; PENILE SWELLING; PENIS DISEASE; PEYRONIE DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETINOPATHY; REVIEW; SEIZURE; SEXUAL FUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRACTION THERAPY; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; CALCIUM CHANNEL BLOCKERS; COLLAGENASES; ELECTRIC STIMULATION THERAPY; HUMANS; INJECTIONS, INTRALESIONAL; IONTOPHORESIS; MALE; PENILE INDURATION; PENIS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PLACEBOS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRACTION;

EID: 84855876259     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2011.45     Document Type: Review

References (86)

1. de La Peyronie F. Sur quelques obstaclesqui sópposent à l'éjaculation nautrelle de la semence. Mem Acad Royale Chir 1743; 1: 337-342.
2. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997; 158: 2284-2290. (Pubitemid 27481391)
3. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-1394.
4. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397-405. (Pubitemid 35285291)
5. Nachtsheim DA, Rearden A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996; 156: 1330-1334. (Pubitemid 26307604)
6. Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani A et al. Immunologic findings in Peyronie's disease: a controlled study. Urology 1997; 50: 764-768. (Pubitemid 27495000)
7. Cantini LP, Ferrini MG, Vernet D, Magee TR, Qian A, Gelfand RA et al. Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008; 5: 1607-1622. (Pubitemid 352044418)
8. Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009; 6: 1284-1296.
9. Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008; 179: 2447-2455.
10. Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007; 4: 485-490. (Pubitemid 46394722)
11. Furlow WL, Swenson Jr HE, Lee RE. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975; 114: 69-71.
12. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376-1379.
13. Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP. A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 1075-1079.
14. Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010; 7: 2359-2374.
15. Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G et al. Pentoxifylline attenuates transforming growth factor-b1-sti-mulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 2010; 7: 2077-2085.
16. Lin G, Shindel AW, Banie L, Ning H, Huang YC, Liu G et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-depen-dent mechanism and downregulation of AAT1. J Sex Med 2010; 7: 1787-1797.
17. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010; 106: 240-248.
18. Althof SE, Corty EW, Levine SB. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793-799. (Pubitemid 29163048)
19. Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (Potabas). J Urol 1959; 81: 770-772.
20. Griffiths MR, Priestley GC. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol 1992; 72: 15-18.
21. Weidner W, Schroeder-Printzen I, Rudnick J. Randomized prospective placebo controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J Urol 1999; 6: 205.
22. Weidner W, Hauck EW, Schnitker J. Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530-536.
23. Furst DE, Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout. In: Bertram G (ed). Basic and Clinical Pharmacology. Katzung Lange: New York, 2001.
24. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169-175.
25. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291-295. (Pubitemid 24246173)
26. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized doubleblind, placebo-controlled study. Int J Impot Res 2004; 16: 238-243. (Pubitemid 38858956)
27. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648-651. (Pubitemid 23001761)
28. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405-409. (Pubitemid 20292836)
29. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003-2005.
30. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88: 63-67.
31. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007; 178(4 Pt 1): 1398-1403. (Pubitemid 47368421)
32. Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948; 41: 173-177.
33. Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002; 14: 353-360. (Pubitemid 35285285)
34. Pryor JP, Farell CF. Controlled clinical trial of Vitamin E in Peyronie's Disease. Prog Reprod Biol 1983; 9: 41-45.
35. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007; 178(4 Pt 1): 1398-1403. (Pubitemid 47368421)
36. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592. (Pubitemid 33126837)
37. Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ. Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010; 30: 540.
38. Bystrom J. Induration penis plastica: experience of treatment with procarbazine natulan. Scand J Urol Nephrol 1976; 10: 21-25.
39. Morgan RJ, Pryor JP. Procarbazine (natulan) in the treatment of Peyronie's disease. Br J Urol 1978; 50: 111-113. (Pubitemid 8344016)
40. Armand JP, Ribrag V, Harroussequ JL, Abrey L. Reappriasal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 2007; 3: 213-224. (Pubitemid 46881449)
41. Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extra-cellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478-5482.
42. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, geno-typic and functional analyses. Int J Impot Res 2002; 14: 397-405. (Pubitemid 35285291)
43. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522-1524. (Pubitemid 24151291)
44. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395-1399. (Pubitemid 27391205)
45. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002; 168: 621-625. (Pubitemid 34793309)
46. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007; 69: 1181-1184. (Pubitemid 46891587)
47. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006; 175: 2115-2118. (Pubitemid 43668536)
48. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620-626. 69: 1181-4. (Pubitemid 28186217)
49. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpa-nah S. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. S Int Urol Nephrol 2009; 41: 467-471.
50. Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y et al. Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med 2010; 7: 3743-3749.
51. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89-94.
52. Wegner HE, Andreson R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha-2b. Eur Urol 1995; 28: 236-240.
53. Wegner HE, Andresen R, Knipsel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32: 190-193. (Pubitemid 27386960)
54. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC et al. Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394-398. (Pubitemid 43833173)
55. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006; 67: 1038.
56. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982; 10: 135-140. (Pubitemid 12046996)
57. Gelbard MK, Linkner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 280-283. (Pubitemid 15006547)
58. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, singlecenter, non-placebo-controlled study. J Sex Med 2008; 5: 180-187.
59. Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J Urol 1993; 149: 56-58. (Pubitemid 23095473)
60. Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA. The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman. J Sex Med 2007; 4: 1209-1213. (Pubitemid 47337663)
61. Taylor FL, Levine LA. Nonsurgical therapy of Peyronie's Disease. Asian J Androl 2008; 10: 79-87.
62. Bodner H, Howard AH, Kaplan JH. Peyronie's Disease cortisone- hyaluronidase hydrocortisone therapy. Trans West Sect AM Urol Assoc 1953; 20: 32-35.
63. Winter CC, Khanna R. Peyronie's Disease: results with dermojet injection of dexamethasone. J Urol 1975; 114: 898-900.
64. Williams G, Green NA. The nonsurgical treatment of Peyr-onie's Disease. Br J Urol 1980; 52: 392-395.
65. Dickstein R, Uberoi J, Munarriz R. Severe, disabling, and/or chronic penile pain associated with Peyronie's Disease: management with subcutaneous steroid injection. J Androl 2010; 31: 445-449.
66. Bartsch G, Menander-Huber KB, Huber W, Marberger H. Orgotein, A new drug for the treatment of Peyronie's Disease. Eur J Rheumatol Inflamm 1981; 4: 250-259. (Pubitemid 11068221)
67. Gustafson H, Johannsson B, Edsmyr F. Peyronie's Disease: experience of local treatment with orgotein. Eur Urol 1981; 7: 346-348. (Pubitemid 11004702)
68. Kendirci M, Trost L, Hellstrom WJG. Intralesional treatment of Peyronie's Disease. In: Levine LA (ed). Peyronie's Disease: A Guide to Clinical Management. Humana Pres Inc: Totowa, NJ, 2007, pp 81-92.
69. Stancik I, Schäfer R, Andrukhova O, Oeser R, Plas E, Pflüger H. Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie's disease. Urology 2009; 74: 566-570.
70. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial. J Urol 2007; 177: 972-975. (Pubitemid 46216345)
71. Weiss DS, Kirsner R, Eaglestein WH. Electrical stimulation and wound healing. Arch Dermatol 1990; 126: 222-225. (Pubitemid 20055695)
72. Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Virgili G, Storti L et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003; 91: 825-829. (Pubitemid 36724069)
73. Levine LA. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003; 15: S113-S120. (Pubitemid 37314339)
74. Hauck EW, Altinkilic BM, Ludwig M, Ludecke G, Schroeder-Printzen I, Arens C et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 2000; 38: 663-670.
75. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009; 56: 363-369.
76. Alenghat FJ, Ingber DE. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE 2002; 2002: PE6.
77. Alman BA, Naber SP, Terek RM, Jiranek WA, Goldberg MJ, Wolfe HJ. Platelet-derived growth factor in fibrous musculos-keletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures. J Orthop Res 1995; 13: 67-77.
78. Brighton CT, Fisher Jr JR, Levine SE, Corsetty JR, Reilly T, Landsman AS et al. The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus. J Bone Joint Surg AM 1996; 78: 1337-1347. (Pubitemid 26336884)
79. Molea G, Schonauer F, Blasi F. Progressive skin extension: clinical and histological evaluation of a modified procedure using Kirschner wires. Br J Plast Surg 1999; 52: 205-208. (Pubitemid 29192728)
80. Shapiro F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 2008; 15: 53-76. (Pubitemid 351958405)
81. Fong KD, Trindade MC, Wang Z, Nacamuli RP, Pham H, Fang TD et al. Microarray analysis of mechanical shear effects on flexor tendon cells. Plast Reconstr Surg 2005; 116: 1393-1404. (Pubitemid 41456513)
82. Levine LA, Newell MM. FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med Devices 2008; 5: 305-310.
83. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009; 6: 558-566.
84. Greenfield JM. Penile traction therapy in Peyronie's disease. F1000 Med Rep 2009; 1. pii: 37.
85. Abern MR, Levine LA. Intralesional verapamil injections with and without penile traction and oral therapies for management of Peyronie's disease. J Urol 2008; 179(Suppl 4): 408.
86. Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie's disease. Drugs 2007; 67: 527-545. (Pubitemid 46440311)